FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365514092> ?p ?o ?g. }

• W4365514092 endingPage "CT022" @default.
• W4365514092 startingPage "CT022" @default.
• W4365514092 abstract "Abstract Background: Tafasitamab, an anti-CD19 immunotherapy that enhances antibody-dependent cellular cytotoxicity and phagocytosis, received accelerated approval in the USA and conditional authorization in Europe in combination with lenalidomide (LEN) for patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) based on the results of the open-label, multicenter, single-arm, Phase II L-MIND study (NCT02399085; Salles G, et al. Lancet Oncol 2020, Duell J, et al. Haematologica 2021). Here, we report the final, 5-year follow-up of L-MIND. Data cut-off was Nov 14, 2022. Methods: Pts were aged ≥18 years with ASCT-ineligible R/R DLBCL, 1-3 prior systemic therapies (including a CD20-targeting regimen), and ECOG PS 0-2. Tafasitamab (12 mg/kg) was given for up to 12 cycles in combination with LEN (25 mg), then as monotherapy until disease progression (PD) or unacceptable toxicity. The primary endpoint was best objective response rate (ORR; complete response [CR] or partial response [PR], by independent radiology committee). Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS), and incidence and severity of adverse events (AEs). Exploratory analyses evaluated efficacy endpoints by prior lines of therapy (pLoT). Results: Of 81 pts enrolled, 80 were treated (full analysis set [FAS]). The ORR (FAS) of 57.5% [95% CI: 45.9-68.5], with CR of 41.2% [30.4-51.6] (n=33) and PR of 16.2% [8.9-26.2] (n=13), was generally consistent with the primary and 3-year analyses. Median DoR was not reached (NR) with median follow up (mFU) of 44.0 months [29.9-57.0]. Median PFS was 11.6 months [5.7-45.7] (mFU 45.6 [22.9-57.6]) and median OS was 33.5 months [18.3-NR] (mFU 65.6 [59.9-70.3]). At data cut-off, OS was &gt;60 months in 21 pts (18 with best response of CR, 1 PR, 1 stable disease and 1 PD), including 14 with 1 pLoT and 7 with ≥2 pLoT. Pts with 1 pLoT (n=40) in the FAS had higher ORR (67.5%; 52.5% CR [n=21] and 15% PR [n=6]) compared to pts with ≥2 pLoT (n=40; 47.5%; 30% CR [n=12] and 17.5% PR [n=7]). However, median DoR was not reached for both subgroups, indicating similar long-term efficacy for responders. AEs were consistent with previous reports and manageable; incidence declined after transition from combination to tafasitamab monotherapy and again with monotherapy &gt;2 years. Conclusion: The final, 5-year analysis of L-MIND showed prolonged durable responses with tafasitamab + LEN combination therapy, followed by long-term tafasitamab monotherapy, in pts with R/R DLBCL ineligible for ASCT, with median DoR not reached after 44 months mFU. No new safety signals were identified, confirming the tolerability profile observed with earlier data cuts. These long-term data suggest that this immunotherapy may have curative potential that is being explored in further studies. Citation Format: Johannes Duell, Pau Abrisqueta, Marc Andre, Marinela Augustin, Gianluca Gaidano, Eva González Barca, Wojciech Jurczak, Nagesh Kalakonda, Anna Marina Liberati, Kami J. Maddocks, Tobias Menne, Zsolt Nagy, Olivier Tournilhac, Abhishek Bakuli, Aasim Amin, Konstantin Gurbanov, Gilles Salles. Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT022." @default.
• W4365514092 created "2023-04-15" @default.
• W4365514092 creator A5007117385 @default.
• W4365514092 creator A5011014349 @default.
• W4365514092 creator A5013293066 @default.
• W4365514092 creator A5014125875 @default.
• W4365514092 creator A5016764336 @default.
• W4365514092 creator A5024389256 @default.
• W4365514092 creator A5031158730 @default.
• W4365514092 creator A5035549893 @default.
• W4365514092 creator A5041745367 @default.
• W4365514092 creator A5048258469 @default.
• W4365514092 creator A5052071966 @default.
• W4365514092 creator A5053541010 @default.
• W4365514092 creator A5053771868 @default.
• W4365514092 creator A5061317839 @default.
• W4365514092 creator A5071466957 @default.
• W4365514092 creator A5074570151 @default.
• W4365514092 creator A5085356385 @default.
• W4365514092 date "2023-04-14" @default.
• W4365514092 modified "2023-10-07" @default.
• W4365514092 title "Abstract CT022: Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study" @default.
• W4365514092 doi "https://doi.org/10.1158/1538-7445.am2023-ct022" @default.
• W4365514092 hasPublicationYear "2023" @default.
• W4365514092 type Work @default.
• W4365514092 citedByCount "1" @default.
• W4365514092 countsByYear W43655140922023 @default.
• W4365514092 crossrefType "journal-article" @default.
• W4365514092 hasAuthorship W4365514092A5007117385 @default.
• W4365514092 hasAuthorship W4365514092A5011014349 @default.
• W4365514092 hasAuthorship W4365514092A5013293066 @default.
• W4365514092 hasAuthorship W4365514092A5014125875 @default.
• W4365514092 hasAuthorship W4365514092A5016764336 @default.
• W4365514092 hasAuthorship W4365514092A5024389256 @default.
• W4365514092 hasAuthorship W4365514092A5031158730 @default.
• W4365514092 hasAuthorship W4365514092A5035549893 @default.
• W4365514092 hasAuthorship W4365514092A5041745367 @default.
• W4365514092 hasAuthorship W4365514092A5048258469 @default.
• W4365514092 hasAuthorship W4365514092A5052071966 @default.
• W4365514092 hasAuthorship W4365514092A5053541010 @default.
• W4365514092 hasAuthorship W4365514092A5053771868 @default.
• W4365514092 hasAuthorship W4365514092A5061317839 @default.
• W4365514092 hasAuthorship W4365514092A5071466957 @default.
• W4365514092 hasAuthorship W4365514092A5074570151 @default.
• W4365514092 hasAuthorship W4365514092A5085356385 @default.
• W4365514092 hasConcept C121332964 @default.
• W4365514092 hasConcept C126322002 @default.
• W4365514092 hasConcept C141071460 @default.
• W4365514092 hasConcept C142424586 @default.
• W4365514092 hasConcept C143998085 @default.
• W4365514092 hasConcept C197934379 @default.
• W4365514092 hasConcept C203092338 @default.
• W4365514092 hasConcept C2776063141 @default.
• W4365514092 hasConcept C2776364478 @default.
• W4365514092 hasConcept C2776694085 @default.
• W4365514092 hasConcept C2777063308 @default.
• W4365514092 hasConcept C2778559949 @default.
• W4365514092 hasConcept C2779338263 @default.
• W4365514092 hasConcept C2780739268 @default.
• W4365514092 hasConcept C2781413609 @default.
• W4365514092 hasConcept C29730261 @default.
• W4365514092 hasConcept C31760486 @default.
• W4365514092 hasConcept C535046627 @default.
• W4365514092 hasConcept C71924100 @default.
• W4365514092 hasConcept C87355193 @default.
• W4365514092 hasConcept C90924648 @default.
• W4365514092 hasConceptScore W4365514092C121332964 @default.
• W4365514092 hasConceptScore W4365514092C126322002 @default.
• W4365514092 hasConceptScore W4365514092C141071460 @default.
• W4365514092 hasConceptScore W4365514092C142424586 @default.
• W4365514092 hasConceptScore W4365514092C143998085 @default.
• W4365514092 hasConceptScore W4365514092C197934379 @default.
• W4365514092 hasConceptScore W4365514092C203092338 @default.
• W4365514092 hasConceptScore W4365514092C2776063141 @default.
• W4365514092 hasConceptScore W4365514092C2776364478 @default.
• W4365514092 hasConceptScore W4365514092C2776694085 @default.
• W4365514092 hasConceptScore W4365514092C2777063308 @default.
• W4365514092 hasConceptScore W4365514092C2778559949 @default.
• W4365514092 hasConceptScore W4365514092C2779338263 @default.
• W4365514092 hasConceptScore W4365514092C2780739268 @default.
• W4365514092 hasConceptScore W4365514092C2781413609 @default.
• W4365514092 hasConceptScore W4365514092C29730261 @default.
• W4365514092 hasConceptScore W4365514092C31760486 @default.
• W4365514092 hasConceptScore W4365514092C535046627 @default.
• W4365514092 hasConceptScore W4365514092C71924100 @default.
• W4365514092 hasConceptScore W4365514092C87355193 @default.
• W4365514092 hasConceptScore W4365514092C90924648 @default.
• W4365514092 hasIssue "8_Supplement" @default.
• W4365514092 hasLocation W43655140921 @default.
• W4365514092 hasOpenAccess W4365514092 @default.
• W4365514092 hasPrimaryLocation W43655140921 @default.
• W4365514092 hasRelatedWork W2009355985 @default.
• W4365514092 hasRelatedWork W2591350172 @default.
• W4365514092 hasRelatedWork W2605009867 @default.
• W4365514092 hasRelatedWork W2795263066 @default.
• W4365514092 hasRelatedWork W2928264246 @default.
• W4365514092 hasRelatedWork W3128028170 @default.
• W4365514092 hasRelatedWork W3172444569 @default.

• next